MX2017004738A - Compuestos aromaticos sustituidos y composiciones farmaceuticas para la prevencion y tratamiento de la diabetes. - Google Patents
Compuestos aromaticos sustituidos y composiciones farmaceuticas para la prevencion y tratamiento de la diabetes.Info
- Publication number
- MX2017004738A MX2017004738A MX2017004738A MX2017004738A MX2017004738A MX 2017004738 A MX2017004738 A MX 2017004738A MX 2017004738 A MX2017004738 A MX 2017004738A MX 2017004738 A MX2017004738 A MX 2017004738A MX 2017004738 A MX2017004738 A MX 2017004738A
- Authority
- MX
- Mexico
- Prior art keywords
- alkenyl
- alkyl
- insulin
- diabetes
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/32—Phenylacetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al uso de los compuestos para prevenir y/o tratar diabetes, para modular los niveles de glucosa, insulina y/o triglicéridos; para reducir el nivel de glucosa en sangre; para mantener o aumentar el nivel de insulina; para aumentar la secreción de insulina; aumentar la sensibilidad a la insulina; o disminuir la resistencia a la insulina en un sujeto. Estos usos novedosos se han descubierto para los compuestos representados por la fórmula I y las sales farmacéuticamente aceptables, en donde A es alquilo C5, alquilo C6, alquenilo C5, alquenilo C6, C(0)-(CH2)n-CH3 o CH(OH)-(CH2)n-CH3 en donde n es 3 o 4, R1 es H, F u OH; R2 es alquilo C5, alquilo C6, alquenilo C5, alquenilo C6, C(O)-(CH2)n-CH3 O CH(OH)-)CH2)n-CH3, en donde n es 3 o 4; R3 es H, F, OH o CH2ph; R4 es H, F u OH; Q es 1) (CH2)m C(O) OH en donde m es 1 o de, 2) CH (CH3) C(O)OH, 3) C(CH3)2 C(O)OH, 4)CH(F)-C(O)OH, 5) CF2- C(O)OH, o 6) C(O)- C(O)OH.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062526P | 2014-10-10 | 2014-10-10 | |
| PCT/CA2015/000531 WO2016054726A1 (en) | 2014-10-10 | 2015-10-08 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017004738A true MX2017004738A (es) | 2017-08-10 |
| MX376872B MX376872B (es) | 2025-03-07 |
Family
ID=55652427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004738A MX376872B (es) | 2014-10-10 | 2015-10-08 | Compuestos aromaticos sustituidos y composiciones farmaceuticas para la prevencion y tratamiento de la diabetes. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10105331B2 (es) |
| EP (1) | EP3203998B1 (es) |
| JP (1) | JP6676629B2 (es) |
| KR (1) | KR20170066614A (es) |
| CN (1) | CN106999458B (es) |
| AR (1) | AR102248A1 (es) |
| AU (1) | AU2015330643B2 (es) |
| BR (1) | BR112017007420A2 (es) |
| CA (1) | CA2963276A1 (es) |
| DK (1) | DK3203998T3 (es) |
| ES (1) | ES2875336T3 (es) |
| IL (1) | IL251392B (es) |
| MX (1) | MX376872B (es) |
| PH (1) | PH12017500662B1 (es) |
| PL (1) | PL3203998T3 (es) |
| PT (1) | PT3203998T (es) |
| RU (1) | RU2723486C2 (es) |
| SG (1) | SG11201702812PA (es) |
| TW (1) | TWI699201B (es) |
| UY (1) | UY36354A (es) |
| WO (1) | WO2016054726A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2723486C2 (ru) * | 2014-10-10 | 2020-06-11 | Прометик Фарма Смт Лимитед | Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения диабета |
| RU2728782C2 (ru) * | 2014-11-12 | 2020-07-31 | Лиминал Байосайенсиз Лимитед | Замещенные ароматические соединения и фармацевтические композиции для ауторепарации и регенерации ткани |
| BR112021006907A2 (pt) | 2018-10-11 | 2021-09-08 | Basf As | Compostos aromáticos e usos farmacêuticos destes |
| CN116568291A (zh) * | 2020-10-06 | 2023-08-08 | 殷格纽制药有限公司 | 取代的芳香族化合物及其药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| JP4697962B2 (ja) * | 2003-02-13 | 2011-06-08 | ウェルスタット セラピューティクス コーポレイション | 代謝性障害の処置のための化合物 |
| AU2005284798B2 (en) * | 2004-09-15 | 2012-02-02 | The President And Fellows Of Harvard College | Reducing ER stress in the treatment of obesity and diabetes |
| AT509045B1 (de) * | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
| JP2012072136A (ja) * | 2010-09-03 | 2012-04-12 | Erina Co Inc | 細胞内代謝促進用組成物、その組成物を含有する糖代謝又は脂質代謝疾患の予防及び／又は治療用医薬製剤、機能性食品及び健康食品 |
| AU2011356584B2 (en) * | 2010-10-27 | 2016-03-10 | Liminal Biosciences Limited | Compounds and pharmaceutical compositions for uses in diabetes |
| TWI689490B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
| RU2723486C2 (ru) * | 2014-10-10 | 2020-06-11 | Прометик Фарма Смт Лимитед | Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения диабета |
-
2015
- 2015-10-08 RU RU2017116106A patent/RU2723486C2/ru active
- 2015-10-08 ES ES15849445T patent/ES2875336T3/es active Active
- 2015-10-08 PH PH1/2017/500662A patent/PH12017500662B1/en unknown
- 2015-10-08 AU AU2015330643A patent/AU2015330643B2/en not_active Ceased
- 2015-10-08 KR KR1020177012551A patent/KR20170066614A/ko not_active Ceased
- 2015-10-08 DK DK15849445.0T patent/DK3203998T3/da active
- 2015-10-08 PL PL15849445T patent/PL3203998T3/pl unknown
- 2015-10-08 CA CA2963276A patent/CA2963276A1/en not_active Abandoned
- 2015-10-08 WO PCT/CA2015/000531 patent/WO2016054726A1/en not_active Ceased
- 2015-10-08 US US15/515,048 patent/US10105331B2/en active Active
- 2015-10-08 BR BR112017007420-6A patent/BR112017007420A2/pt not_active Application Discontinuation
- 2015-10-08 PT PT158494450T patent/PT3203998T/pt unknown
- 2015-10-08 JP JP2017518943A patent/JP6676629B2/ja not_active Expired - Fee Related
- 2015-10-08 SG SG11201702812PA patent/SG11201702812PA/en unknown
- 2015-10-08 EP EP15849445.0A patent/EP3203998B1/en active Active
- 2015-10-08 MX MX2017004738A patent/MX376872B/es active IP Right Grant
- 2015-10-08 CN CN201580066107.9A patent/CN106999458B/zh not_active Expired - Fee Related
- 2015-10-12 TW TW104133395A patent/TWI699201B/zh not_active IP Right Cessation
- 2015-10-13 AR ARP150103296A patent/AR102248A1/es unknown
- 2015-10-13 UY UY0001036354A patent/UY36354A/es not_active Application Discontinuation
-
2017
- 2017-03-26 IL IL251392A patent/IL251392B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US10105331B2 (en) | 2018-10-23 |
| TW201618763A (zh) | 2016-06-01 |
| RU2017116106A (ru) | 2018-11-12 |
| CA2963276A1 (en) | 2016-04-14 |
| JP6676629B2 (ja) | 2020-04-08 |
| TWI699201B (zh) | 2020-07-21 |
| CN106999458B (zh) | 2021-04-13 |
| IL251392A0 (en) | 2017-05-29 |
| KR20170066614A (ko) | 2017-06-14 |
| PL3203998T3 (pl) | 2021-09-27 |
| EP3203998A1 (en) | 2017-08-16 |
| EP3203998B1 (en) | 2021-03-10 |
| BR112017007420A2 (pt) | 2018-01-16 |
| DK3203998T3 (da) | 2021-05-31 |
| AU2015330643B2 (en) | 2020-05-14 |
| SG11201702812PA (en) | 2017-05-30 |
| CN106999458A (zh) | 2017-08-01 |
| WO2016054726A1 (en) | 2016-04-14 |
| MX376872B (es) | 2025-03-07 |
| US20170209399A1 (en) | 2017-07-27 |
| AU2015330643A1 (en) | 2017-05-04 |
| RU2017116106A3 (es) | 2019-02-13 |
| AR102248A1 (es) | 2017-02-15 |
| ES2875336T3 (es) | 2021-11-10 |
| PT3203998T (pt) | 2021-06-07 |
| UY36354A (es) | 2016-06-01 |
| RU2723486C2 (ru) | 2020-06-11 |
| PH12017500662A1 (en) | 2017-10-02 |
| EP3203998A4 (en) | 2018-06-20 |
| PH12017500662B1 (en) | 2022-08-19 |
| JP2017530182A (ja) | 2017-10-12 |
| IL251392B (en) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37845A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| MX2020000261A (es) | Nuevos compuestos. | |
| UY37363A (es) | Sulfonilureas y compuestos relacionados y sus usos | |
| MX2015011878A (es) | Compuestos aromaticos sustituidos y metodo relacionado para el tratamiento de la fibrosis. | |
| UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
| GT201400031A (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
| CO6400220A2 (es) | Derivados de sulfonamida | |
| MX2022011354A (es) | Compuestos de pirimidina fusionados como moduladores de kcc2. | |
| PE20151375A1 (es) | Compuestos ciclicos eter pirazol-4-il-heterociclil-carboxamida y metodos de utilizacion | |
| UY31906A (es) | Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias. | |
| MX2015012886A (es) | Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca. | |
| CR20130432A (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| CR10614A (es) | Derivados heterociclicos fusionados y metodos de uso | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| ES2564010T3 (es) | Composición farmacéutica para tratar o prevenir el glaucoma | |
| ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
| MX2017004738A (es) | Compuestos aromaticos sustituidos y composiciones farmaceuticas para la prevencion y tratamiento de la diabetes. | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| MX2017004733A (es) | Compuestos aromaticos sustituidos y composiciones farmaceuticas para la prevencion y tratamiento de osteoporosis. | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |